Published in Biotech Business Week, December 26th, 2005
The randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the efficacy and safety of MMF to maintain or improve symptom control with reduced corticosteroids in patients with myasthenia gravis over a treatment period of 36 weeks. The primary endpoint of responder status in the trial encompasses both minimal disease activity and low...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.